Abstract
γ-Secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimers disease (AD). This novel concept of manipulating the cleavage specificity of the γ-secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-β(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease. Following on from the initial discovery that certain non-steroidal anti-inflammatory drugs (NSAIDs) exhibit properties characteristic of γ-secretase modulators, this class of compounds has been extensively studied and exploited, leading to the discovery of NSAIDs derivatives endowed with improved potency for the reduction of amyloid-β(1-42) peptide production. In addition, a very limited number of non-NSAID derived γ-secretase modulators has also been recently claimed in the patent literature, suggesting that only a restricted number of pharmacophores might be involved in the modulation of γ-secretase.
Current Topics in Medicinal Chemistry
Title: γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective
Volume: 8 Issue: 1
Author(s): Ilaria Peretto and Elena La Porta
Affiliation:
Abstract: γ-Secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimers disease (AD). This novel concept of manipulating the cleavage specificity of the γ-secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-β(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease. Following on from the initial discovery that certain non-steroidal anti-inflammatory drugs (NSAIDs) exhibit properties characteristic of γ-secretase modulators, this class of compounds has been extensively studied and exploited, leading to the discovery of NSAIDs derivatives endowed with improved potency for the reduction of amyloid-β(1-42) peptide production. In addition, a very limited number of non-NSAID derived γ-secretase modulators has also been recently claimed in the patent literature, suggesting that only a restricted number of pharmacophores might be involved in the modulation of γ-secretase.
Export Options
About this article
Cite this article as:
Peretto Ilaria and Porta La Elena, γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334097
DOI https://dx.doi.org/10.2174/156802608783334097 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Effect of the Acute Phase Response Induced by Endotoxin Administration on the Expression and Activity of UGT Isoforms in Rats
Drug Metabolism Letters Aging and immunopathology in primary Sjögren's syndrome
Current Aging Science Enzyme Inhibitors
Current Bioactive Compounds Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Current Drug Safety Gut Microbiota and Alzheimer’s Disease: Experimental Evidence and Clinical Reality
Current Alzheimer Research The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
Current Neurovascular Research Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy F2-Isoprostanes: Review of Analytical Methods
Current Pharmaceutical Analysis Effects of α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator on BDNF, NKCC1 and KCC2 Expression in the Hippocampus following Lipopolysaccharide-Induced Allodynia and Hyperalgesia in a Mouse Model of Inflammatory Pain
CNS & Neurological Disorders - Drug Targets Gene Therapy: How to Target the Kidney. Promises and Pitfalls
Current Gene Therapy